Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Temozolomide in Primary CNS Lymphoma
NCT02113007Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab and temozolomide in primary central nervous system lymphoma (PCNSL), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 32 weeks. Started Jul 2014; status: terminated.
02
Drugs
rituximabtemozolomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT02113007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113007.